Methods for the treatment of tinnitus induced by cochlear excitotoxicity
AssigneeAuris Medical AG
InventorsMatthieu Guitton, Jean-Luc Puel, Remy Pujol, Jerome Ruel, Jing Wang
Life of this patent
Estimating the term…
Loading patent…
AssigneeAuris Medical AG
InventorsMatthieu Guitton, Jean-Luc Puel, Remy Pujol, Jerome Ruel, Jing Wang
Estimating the term…
The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.
A method for treating tinnitus induced by cochlear excitotoxicity in a human, the method comprising administering to a human a therapeutically effective amount of a pharmaceutical composition comprising an NMDA receptor antagonist ketamine, effective to suppress or reduce NMDA receptor mediated aberrant activity of the auditory nerve in a human in need of such treatment.
A method for treating tinnitus induced by cochlear excitotoxicity in a human, the method comprising administering to a human a therapeutically effective amount of a pharmaceutical composition comprising an NMDA receptor antagonist ketamine, effective to treat NMDA receptor mediated aberrant activity of the auditory nerve in a human in need of such treatment.
Dependencies are inferred from the claim text.